Projected life expectancy of people with HIV according to timing of diagnosis

被引:354
作者
Nakagawa, Fumiyo [1 ]
Lodwick, Rebecca K. [1 ]
Smith, Colette J. [1 ]
Smith, Ruth [2 ]
Cambiano, Valentina [1 ]
Lundgren, Jens D. [3 ,4 ]
Delpech, Valerie [2 ]
Phillips, Andrew N. [1 ]
机构
[1] UCL, Res Dept Infect & Populat Hlth, HIV Epidemiol & Biostat Grp, London NW3 2PF, England
[2] Hlth Protect Agcy, London, England
[3] Univ Copenhagen, Panum Inst, Copenhagen HIV Programme, DK-2200 Copenhagen, Denmark
[4] Copenhagen Univ Hosp, Dept Infect Dis, Ctr Viral Dis, Copenhagen, Denmark
关键词
antiretroviral therapy; diagnosis; life expectancy; model; ACTIVE ANTIRETROVIRAL THERAPY; CD4 CELL COUNT; VIROLOGICAL FAILURE; INFECTED PATIENTS; NORTH-AMERICA; VIRAL LOAD; AIDS; MORTALITY; RISK; SURVIVAL;
D O I
10.1097/QAD.0b013e32834dcec9
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background and objectives: Effective antiretroviral therapy (ART) has contributed greatly toward survival for people with HIV, yet many remain undiagnosed until very late. Our aims were to estimate the life expectancy of an HIV-infected MSM living in a developed country with extensive access to ART and healthcare, and to assess the effect of late diagnosis on life expectancy. Methods: A stochastic computer simulation model of HIV infection and the effect of ART was used to estimate life expectancy and determine the distribution of potential lifetime outcomes of an MSM, aged 30 years, who becomes HIV positive in 2010. The effect of altering the diagnosis rate was investigated. Results: Assuming a high rate of HIV diagnosis (median CD4 cell count at diagnosis, 432 cells/mu l), projected median age at death (life expectancy) was 75.0 years. This implies 7.0 years of life were lost on average due to HIV. Cumulative risks of death by 5 and 10 years after infection were 2.3 and 5.2%, respectively. The 95% uncertainty bound for life expectancy was (68.0,77.3) years. When a low diagnosis rate was assumed (diagnosis only when symptomatic, median CD4 cell count 140 cells/mu l), life expectancy was 71.5 years, implying an average 10.5 years of life lost due to HIV. Conclusion: If low rates of virologic failure observed in treated patients continue, predicted life expectancy is relatively high in people with HIV who can access a wide range of antiretrovirals. The greatest risk of excess mortality is due to delays in HIV diagnosis. (C) 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
引用
收藏
页码:335 / 343
页数:9
相关论文
共 49 条
  • [31] Survival of persons with and without HIV infection in Denmark, 1995-2005
    Lohse, Nicolai
    Hansen, Ann-Brit Eg
    Pedersen, Gitte
    Kronborg, Gifte
    Gerstoft, Jan
    Sorensen, Henrik Toft
    Vaeth, Michael
    Obel, Niels
    [J]. ANNALS OF INTERNAL MEDICINE, 2007, 146 (02) : 87 - 95
  • [32] Cardiovascular Risk Assessment in Antiretroviral-Naive HIV Patients
    Maggi, Paolo
    Quirino, Tiziana
    Ricci, Elena
    De Socio, Giuseppe Vittorio L.
    Gadaleta, Aurora
    Ingrassia, Fabrizio
    Perilli, Francesco
    Lillo, Antonio
    Bonfanti, Paolo
    [J]. AIDS PATIENT CARE AND STDS, 2009, 23 (10) : 809 - 813
  • [33] May MT, 2006, LANCET, V368, P451, DOI 10.1016/S0140-6736(06)69152-6
  • [34] Virological rebound after suppression on highly active antiretroviral therapy
    Mocroft, A
    Ruiz, L
    Reiss, P
    Ledergerber, B
    Katlama, C
    Lazzarin, A
    Goebel, FD
    Phillips, AN
    Clotet, B
    Lundgren, JD
    [J]. AIDS, 2003, 17 (12) : 1741 - 1751
  • [35] Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
    Palella, FJ
    Delaney, KM
    Moorman, AC
    Loveless, MO
    Fuhrer, J
    Satten, GA
    Aschman, DJ
    Holmberg, SD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (13) : 853 - 860
  • [36] Expanded screening for HIV in the United States - An analysis of cost-effectiveness
    Paltiel, AD
    Weinstein, MC
    Kimmel, AD
    Seage, GR
    Losina, E
    Zhang, H
    Freedberg, KA
    Walensky, RP
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (06) : 586 - 595
  • [37] HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load
    Phillips, AN
    Staszewski, S
    Weber, R
    Kirk, O
    Francioli, P
    Miller, V
    Vernazza, P
    Lundgren, JD
    Ledergerber, B
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (20): : 2560 - 2567
  • [38] Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study
    Phillips, Andrew N.
    Leen, Clifford
    Wilson, Alan
    Anderson, Jane
    Dunn, David
    Schwenk, Achim
    Orkin, Chloe
    Hill, Teresa
    Fisher, Martin
    Walsh, John
    Pillay, Deenan
    Bansi, Loveleen
    Gazzard, Brian
    Easterbrook, Philippa
    Gilson, Richard
    Johnson, Margaret
    Sabin, Caroline A.
    [J]. LANCET, 2007, 370 (9603) : 1923 - 1928
  • [39] HIV in the UK 1980-2006: Reconstruction using a model of HIV infection and the effect of antiretroviral therapy
    Phillips, Andrew N.
    Sabin, C.
    Pillay, D.
    Lundgren, J. D.
    [J]. HIV MEDICINE, 2007, 8 (08) : 536 - 546
  • [40] The role of HIV in serious diseases other than AIDS
    Phillips, Andrew N.
    Neaton, James
    Lundgren, Jens D.
    [J]. AIDS, 2008, 22 (18) : 2409 - 2418